Navigation Links
Tarix Pharmaceuticals' Peptide Technology Stimulates Revascularization Following Ischemia
Date:3/5/2013

CAMBRIDGE, Mass., March 5, 2013 /PRNewswire/ -- Tarix Pharmaceuticals, a biopharmaceutical company focused on developing novel, peptide-based therapies to treat a range of critical medical conditions, today announced it has uncovered a new role for its therapeutic peptides in stimulating revascularization following ischemia. 

In models of ischemic stroke and peripheral vascular disease, treatment with either the Company's natural peptide, TXA127, or its cyclic analog, PanCyte, resulted in increased blood flow and histologic evidence of vasculogenesis (new blood vessel formation).

Rick Franklin , CEO of Tarix Pharmaceuticals, stated, "We explored the therapeutic value of our peptides following ischemia, due to their stimulatory effect on endothelial progenitor cells, which are increased naturally during ischemia and play an important role in vascular regeneration.  We were very pleased, and somewhat surprised, at the efficacy seen in these models in which we saw a return to near-normal blood flow that correlated with histologic evidence of new vessel formation. In addition, in multiple models of ischemic stroke recovery, there was significant improvement in a variety of clinically relevant neurologic measurements."

Franklin continued, "Given this compelling data, we are now planning to initiate clinical trials in ischemic stroke and peripheral vascular disease in 2013."

The transient middle cerebral artery occlusion stroke model involved fifteen animals per treatment group, and was randomized and blinded. There were significant improvements in neurologic score, forelimb placement, stepping test and body swing test, all of which are standard measurements of functional response in stroke. Treatment was begun twenty-four hours after the stroke, and positive results were detectable within two weeks, and improvement continued throughout the seven-week study. In addition, there was a substantial increase in cerebral blood flow and histologic evidence of new blood vessel formation.

Separately, in a mouse model of unilateral hindlimb ischemia, ischemic recovery was compared between TXA127 or PanCyte treatment versus control animals.  Blood flow in treated animals improved significantly faster toward normal, with percent blood flow more than double that of control animals by day 49 (~85% vs ~40%).  Histologic examination again showed a significant increase in the number of functional blood vessels amongst treated animals compared to controls.

About Tarix Pharmaceuticals
Tarix Pharmaceuticals is a biopharmaceutical company focused on developing novel, peptide-based therapies to treat a range of critical medical conditions.  Tarix' proprietary technology platform consists of TXA127, a pharmaceutical formulation of the naturally occurring peptide, Angiotensin (1-7), and PanCyte, a cyclic analogue of TXA127 with an extended half-life.  TXA127 and PanCyte have shown striking effects in models of ischemic stroke and peripheral vascular disease through improvement in endothelial progenitor cell number and function. The peptides have also been effective in models of diabetes. Tarix intends to initiate clinical trials in these indications during 2013, adding to its clinical pipeline that includes multiple programs in hematopoiesis.For Tarix Pharmaceuticals:

Media / Investor Contacts:Rick Franklin

Jason Rando / Claire Sojda Rick.franklin@tarixpharma.com

Tiberend Strategic Advisors, Inc.212.827.0020jrando@tiberend.comcsojda@tiberend.com


'/>"/>
SOURCE Tarix Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Unigene and Tarix Pharmaceuticals Report Highly Increased Oral Bioavailability of "Peptelligence-engineered" TXA127
2. Unigene and Tarix Pharmaceuticals Enter Definitive Licensing Agreement for "Peptelligence-Engineered" TXA127
3. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
4. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
5. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
6. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
7. Icahn Issues Statement Regarding Amylin Pharmaceuticals
8. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
9. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
10. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
11. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... -- West Pharmaceutical Services, Inc. (NYSE: WST), ... administration, today announced that it will release third-quarter 2017 ... 26, 2017, and will follow with a conference call ... a.m. Eastern Time. To participate on the call, please ... is 94093362. A ...
(Date:10/10/2017)... 2017  NDS received FDA 510(k) clearance in May 2017 for ... stand specifically designed for endoscopy environments. An innovative secondary monitor solution, ... solution to support the improvement of patient outcomes, procedural efficiency, and ... ... ...
(Date:10/4/2017)... WESTWOOD, Mass. , Oct. 4, 2017  According to the Centers ... by the end of October . PhysicianOne Urgent Care is helping communities ... Westchester, NY , by offering no-cost* flu shots through ... , as mandated by certain health insurance regulations. ... The best time to get a flu shot is by ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has released a ... books in the Holy Scriptures, Revelation. The Book of Revelation paints a picture of ... have tossed it off as mere rubbish, but Yisrayl Hawkins says that is because ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the ... “America On The Brink” is the creation of published author, William Nowers. Captain ... As a WWII veteran, he spent thirty years in the Navy. Following his ...
(Date:10/12/2017)... Wis. (PRWEB) , ... October 12, 2017 , ... ... standard products to meet the demand of today’s consumer and regulatory authorities worldwide. ... of probiotic experts and tested to meet the highest standard. , These ...
(Date:10/12/2017)... Maryland (PRWEB) , ... October 12, 2017 , ... ... magnetic drug delivery system that we intend to develop to enable prevention of ... can lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, the Health & Wellness ... Moonlight to raise money for the American Heart Association Heart Walk. Teams of up ... work together to keep their treadmills moving for 5 hours. Treadmills will start at ...
Breaking Medicine News(10 mins):